Home/News Feed/New Phase 3 data show ICOTYDE provides lasting skin clearance in moderate-to-severe plaque psoriasis over two years. Johnson & Johnson announced two-year Phase 3 results for ICOTYDE (icotrokinra), an oral peptide targeting IL-23 receptor 1, showing sustained high skin clearance rates in adults and adolescents with moderate-to-severe plaque psoriasis. Nearly 72% of patients achieved 90% improvement in psoriasis severity, with over 70% having clear or almost clear skin at two years, alongside a consistent safety profile. These results highlight ICOTYDE as a promising long-term systemic therapy option, with ongoing studies exploring its use in related inflammatory diseases.
Johnson & Johnson shares trade at USD 255.71 on Pluang as of Oct 09, 2026 18:11 WIB, down 0.30% for the day. The stock holds a market cap of $618.09 billion, reflecting strong investor interest despite the slight dip. Most Pluang users are buying, with 96% of order activity favoring purchases, showing confidence in the company amid its new long-term data announcement.